Pharma and Self-Perception: Knights, Knaves or Pawns?

Pharma and Self-Perception: Knights, Knaves or Pawns?

Even the industry's sunniest personalities don't deny that pharma has an image problem among outside constituencies, with an unfortunately high percentage of observers believing the biz is first and foremost about profits. Sachin Jain dives deep on this and other perceptions—accurate and otherwise—about the industry and its marketing machinery

Partner Forum: Social for HCPs—Is Now the Time?

The increasing use of social media to reach consumers in the healthcare arena raises questions: Is it time to leverage it for HCPs, and if so, what are the most viable platforms for pharma-HCP communications?

Private View: Elliott Smith

Private View: Elliott Smith

EHR Update: Record Correction

EHR Update: Record Correction

Of all the channels through which brands can connect with HCPs, electronic health records have long been considered the most stubbornly and frustratingly impenetrable. Might advances in analytics and cloud technology, among other recent innovations, help simplify the EHR equation? Sarah Mahoney investigates

Loyalty Programs: Beyond the Co-Pay Card

Loyalty Programs: Beyond the Co-Pay Card

In the past, when pharma companies talked about patient-loyalty programs, what they were really talking about were the financial incentives underpinning them. But in the wake of Novo Nordisk's successful support program for diabetics, Cornerstones4Care, such initiatives are finally set to evolve. James Chase reports on the shifting focus of patient support

FDA Policy: Is Off-Label on the Table?

FDA Policy: Is Off-Label on the Table?

In years past pharma marketers had to check themselves before conveying off-label product claims, even though those off-label uses had long since become standards of care. But in recent months the FDA has signaled a willingness to open the off-label information floodgates. Former FDA Associate Commissioner Peter Pitts explains exactly why this matters

Pharma Report: A Sunny Day in Pharmaland

Pharma Report: A Sunny Day in Pharmaland

The year 2014 stunned even the sunniest of pharmaceutical optimists. Read our report

Headliner: Pfizer's mentoring maestro hones his craft

Headliner: Pfizer's mentoring maestro hones his craft

The Healthcare Businesswoman's Association 2015 Honorable Mentor has elevated mentoring to a prominent place.

SkillSets: Omnicare Inc.

SkillSets: Omnicare Inc.

A monthly showcase of companies offering expertise, experience and services within specific areas of the industry. This month: Rare Diseases

Engaging HCPs: Rep and a Hard Place

Engaging HCPs: Rep and a Hard Place

Technology has, quite clearly, transformed the role of the sales rep. But at the same time, predictions that the rep would go the way of the dodo bird have themselves been proved false. James Chase surveys the rep's role in a changing media and sales environment

Headliner: Dexcom device executive presses connectivity

Headliner: Dexcom device executive presses connectivity

"Some people wake up in the middle of the night worrying about business," Kevin Sayer says. But when he wakes up he can't sleep because he's so excited!

Therapeutic Focus: Respiratory

Therapeutic Focus: Respiratory

The respiratory field, in which several launches are under way, is branching out, from long-time dominant fixed-dose combinations to a therapeutic arsenal that includes biologics and gene therapy. Rebecca Mayer Knutsen investigates the innovation and the intrigue

Rare Diseases: Target Practice

Rare Diseases: Target Practice

The orphan-drug market was flying high before President Obama announced plans to devote $215 million to the funding of a Precision Medicine Initiative. Imagine the excitement among interested audiences now that those plans have picked up momentum. Frank Celia reports

DTC Report: DTC Unbound

DTC Report: DTC Unbound

DTC pharma advertising works—ask anyone. But over the years, its effectiveness has been blunted by FDA requirements that, marketers claim, befog rather than clarify. Larry Dobrow surveys the DTC landscape in the wake of the FDA's new—and some say revolutionary—guidance for communicating risk information in print ads

DTC Report: Ten Best DTC Ads of 2014

DTC Report: Ten Best DTC Ads of 2014

Below, a review of last year's 10 best DTC ads, excerpted from MM&M's April cover story, "DTC Report: DTC Unbound," which will be viewable online on Wednesday, March 25. Mary Skoyles reports

Think Tank: There's Work to Do

Five digital pharma experts benchmark the industry's progress and project the next big digital trends

Consumers: Patients and Virtues

Consumers: Patients and Virtues

Consumers come with the same basic set of instructions as HCPs—find out what they need, then offer meaningful solutions. But be warned: Shiny objects may cause a temporary loss of vision

Healthcare Professionals: Chaos Breeds Opportunity

Healthcare Professionals: Chaos Breeds Opportunity

Increasingly pressed for time, the last thing physicians need is more engagement opportunities with pharma, right? Wrong. It's all about offering the right content in the right format at the right time

Overview: Can't, Won't, Don't Stop

Overview: Can't, Won't, Don't Stop

As pharma continues to scale the digital curve, James Chase's assessment of the landscape paints a familiar picture of progress and encouragement mixed with frustration and pain

Skill Sets: Cello Health Insight

Skill Sets: Cello Health Insight

A monthly showcase of companies offering expertise, experience and services within specific areas of the industry. In this edition: multichannel marketing

MAHF 2015: An Evening of Icons

MAHF 2015: An Evening of Icons

The industry celebrated its most precious asset—its people—at The Pierre in New York City on February 3 with a dinner honoring the two most recent inductees to the Medical Advertising Hall of Fame and the 2015 "Future Famers"

How to Win an MM&M Award: 2015

How to Win an MM&M Award: 2015

You have fewer than six weeks to enter the MM&M Awards. No problem. Follow our checklist of Do's and Don'ts and tune in to our webcast on March 24 for more tips.

Partner Forum: Can evidence show POC the way?

EHRs can deliver evidence-based information about giving the right medicine to the right patient at the right time. How can industry craft point-of-care marketing that is both relevant and useful?

Marketing Research: Collaboration Proclamation

Marketing Research: Collaboration Proclamation

The combination of EHR, sensor and biomarker data is working to break down traditional barriers to collaboration among top-flight HEOR researchers

Multichannel Marketing: Multichannel Matures

Multichannel Marketing: Multichannel Matures

Most healthcare marketers understand the need for their programs to live in a range of channels. Now comes the hard part: Balancing their efforts across the multichannel spectrum. Michael Spitz offers some advice to marketers who get the "why" but need some help with the "how"

Mobile Marketing: It's Go Time

Mobile Marketing: It's Go Time

The sales reps are game, the HCPs are receptive and the mobile technology is ready. Rebecca Mayer Knutsen reports on the circumstances that have converged to provide pharma with its most promising mobile selling moment to date

Therapeutic Focus: Metabolic

Therapeutic Focus: Metabolic

Is this finally the year that anti-obesity drugs make the leap from niche curio to mainstream therapy? Frank Celia reports on the changing practitioner mind-set that could shift odds in favor of several new weight-loss options

Formulary Fireworks

Formulary Fireworks

In the wake of the high-profile showdown between Gilead and Express Scripts over the pricing of hepatitis-C drugs Sovaldi and Harvoni, the pharma/PBM balance of power may well have shifted—but not to the degree that many observers had predicted

Journal Ad Review: Back in the Mix

Journal Ad Review: Back in the Mix

A few years ago medical publishers were approaching a cliff and the choices were simple: Evolve the business or fall over the edge. By having learned to survive, some publishers are now ready to thrive

Headliner: New Synta chief adds commercialization clout

Headliner: New Synta chief adds commercialization clout

Anne Whitaker, President and CEO, Synta Pharmaceuticals

MM&M Awards—Fields of Gold

MM&M Awards—Fields of Gold

The MM&M Awards 2015 program is officially open for business

Nothing (Im)personal

Nothing (Im)personal

With unprecedented numbers of practices locking out sales reps, pharma companies are being forced to do a better job of engaging HCPs in other ways

Men of Agency

Men of Agency

Francis Gace and Dr. H. James Barnum took different paths to the top but each left a lasting mark on the advertising business. Barbara Peck celebrates the legacies of the two latest inductees to the Medical Advertising Hall of Fame

Hot Space

Hot Space

Our second annual survey of patients, physicians and payers reveals a significant degree of frustration—on every side—in an around the ever-booming specialty drug segment. Sarah Morgan interprets the results

Therapeutic Focus: Rare Diseases

Therapeutic Focus: Rare Diseases

The rare disease drug market is making history with its steady growth and burgeoning pipeline—and owing to continuing breakthroughs in gene therapy, the biggest advances are yet to come. Rebecca Mayer Knutsen reports on a sector that is thriving—and on the possibility that issues around pricing can slow its surge.

Headliner: Scientist CEO sets sights on Sierra Leone

Headliner: Scientist CEO sets sights on Sierra Leone

Thomas Sack, President and CEO, MRIGlobal

CROs: Trial Blazing

CROs: Trial Blazing

Running clinical trials remains one of Big Pharma's biggest headaches. But thanks to canny use of social media, gamification techniques and even text messages, CROs have revitalized and revolutionized the process. Barbara Peck explains

Data Management: Brace for the Breach

Data Management: Brace for the Breach

The specter of a massive hack is haunting the healthcare industry. As it turns out, that might not necessarily be a bad thing for everyone involved. Sarah Mahoney explains

The Pipeline Report 2015: Dream Drugs

The Pipeline Report 2015: Dream Drugs

These 16 sprouts, from a field of 156, are looking up. With more nurturing, their buds could blossom. Marc Iskowitz reports

Outlook 2015: Street Science

Outlook 2015: Street Science

Buoyed by unprecedented success in hepatitis C, the biotech and pharma sectors had a strong 2014. And to hear ace Evercore ISI analyst Dr. Mark Schoenebaum tell it, everything's in place for growth in 2015 and beyond. Here, he takes both a look back and a look forward

Outlook 2015: The Tax Man Cometh

Outlook 2015: The Tax Man Cometh

For years, Congress has batted around the possibility of tax reform—and with it, the reduction or elimination of the tax deduction for marketing expenses. Could 2015 be the year that reform comes to pass? Larry Dobrow attempts to answer this and other pressing policy questions

Headliner: Pharma vet charts consultancy course

Headliner: Pharma vet charts consultancy course

Dennis Urbaniak, managing director, Accenture Life Sciences

MM&M Awards 2014: Gazing at the Stars

MM&M Awards 2014: Gazing at the Stars

Standouts from the pharma, agency and media worlds aligned on the evening of October 2, as the industry saluted the winners of the 2014 MM&M Awards. Click on the slideshow below to see a gallery of pictures from the event

Leadership Exchange: Engaging the Digital Natives

Leadership Exchange: Engaging the Digital Natives

Striking the right tone in health communications with digital-savvy Millennials is tricky. Marc Iskowitz asks seven experts for some of the keys to facilitating that conversation

Therapeutic Focus 2014: Neurology

Therapeutic Focus 2014: Neurology

New therapies are shaking up MS and insomnia, while the slow pace of progress in Alzheimer's continues to frustrate patients and physicians alike. Welcome to neurology, where, Joe Dysart reports, treatment breakthroughs in certain areas are counteracted by setbacks in others

Cloud Marketing: Cloud Power

Cloud Marketing: Cloud Power

For all the talk about "the cloud," it promises most players in the pharma loop—sales and marketing execs, R&D teams and even the FDA—a better and faster way of doing business. Sarah Mahoney reports on how "the cloud" has become much more than a buzzword, and on what's inhibiting adoption

Point of Care: Ready to Wear

Point of Care: Ready to Wear

For the last few years, technology companies have been far more bullish about the potential of wearable health devices than healthcare organizations, never mind the consumers who were supposedly so eager to embrace them. New research, however, reveals that wearables may finally be catching on. Parks Associates' Harry Wang explains

Informed Targeting: Target Practice

Informed Targeting: Target Practice

As traditional saturation detailing and speaker programs lose ground, the advent of big data and analytics is letting pharma companies reach prized prescribers through new techniques like informed targeting and dynamic marketing. ZS Associates' Pratap Khedkar and Malcolm Sturgis explain

Engaging HCPs: Inhospitable

Engaging HCPs: Inhospitable

Hospitals used to be much more welcoming to pharma sales reps than they are today. Larry Dobrow looks at how the rise of the hospitalist has changed the game plan for getting the word out about products

Therapeutic Focus 2014: Vaccines

Therapeutic Focus 2014: Vaccines

The anti-vaccination movement continues to make noise, but the Ebola scare has highlighted the role vaccines play in controlling diseases—and saving lives. Joe Dysart looks at the implications of the quest for an anti-Ebola vaccine, as well as the corporate shakeup in the vaccine sector.

Career Paths: The Climb

Career Paths: The Climb

As these eight pharma execs tell Larry Dobrow, achieving long-term success takes learning, listening, adapting and connecting with colleagues

Career & Salary Survey: In Check

Career & Salary Survey: In Check

Salaries are down,the industry gender gap persists and people have their eyes peeled for better gigs. But job satisfaction remains positive and, compared with other businesses, the pay isn't half-bad. James Chase attempts to make sense of the seeming contradictions

Headliner: HealthSpot's teleconnected CEO

Headliner: HealthSpot's teleconnected CEO

Steve Cashman, Founder and CEO, HealthSpot

Recruitment: The New Breed

Recruitment: The New Breed

What do healthcare agencies really want when it comes to potential employees? The answer to that question is in a constant state of flux, as technologies, clients' changing demands and the ever-expanding skill sets of a new generation of job seekers are transforming the rules of recruitment and hiring. Larry Dobrow reports

Therapeutic Focus 2014: Women's Health

Therapeutic Focus 2014: Women's Health

To see what's new in the women's health market, it might be necessary to take a look back. The return of the IUD is just one comeback shaping the future of a field that has never been a stranger to controversy. Noah Pines reports on the latest developments in this space

Patient Education/ Marketing: Keeping Pace with Patients

Patient Education/ Marketing: Keeping Pace with Patients

Welcome to patient education circa 2014: With patient expectations at an all-time high, pharma marketers are struggling to keep up in the quest to make meaningful contact with tech-empowered audiences. But a few savvy companies seem to have cracked the communication code, moving to the forefront of this movement. Larry Dobrow reports

Journal Ad Review: Reality Bites

Journal Ad Review: Reality Bites

Print's numbers may be taking some small steps in the right direction, but data is what the industry really wants to sink its teeth into. Larry Dobrow reports on what 2014's slight uptick means in the context of an evolving media mix

Headliner: Proteus CEO takes an original path

Headliner: Proteus CEO takes an original path

Andrew Thompson, CEO, Proteus Digital Health

Leadership Exchange: How Do We Get Beyond the Pill?

Leadership Exchange: How Do We Get Beyond the Pill?

As its focus moves from manufacturing to service, pharma needs to partner with healthcare neophytes as well as established players. James Chase asks six experts to assess the risks and opportunities

Headliner: Galderma CEO confronts challenges

Headliner: Galderma CEO confronts challenges

Stuart Raetzman, CEO, Galderma Labs

MM&M Awards 2014: The Final Cut

MM&M Awards 2014: The Final Cut

More than 100 esteemed industry leaders and thinkers spent several hours discussing, reviewing and scoring around 700 entries to the MM&M Awards. Here are the results of their efforts—the 2014 finalists

Multichannel Marketing: At Your Service

Multichannel Marketing: At Your Service

Pharma is moving toward a broader treatment paradigm based on providing additional services for patients. Boris Kushkuley describes what the Pill+ model looks like, and how multichannel marketing can facilitate it

Therapeutic Focus 2014: Oncology

Therapeutic Focus 2014: Oncology

Immunotherapy is an emerging powerhouse in cancer treatment. Early gains being made in multiple tumor types provide a glimpse of the effectiveness of several agents and regimens. While longer follow-up is needed, the results have analysts talking about a big shift in the war on cancer. Joe Dysart reports

Marketing Research: A Question of Value

Marketing Research: A Question of Value

When assessing the value of breakthrough drugs, Health Economics & Outcomes Research can help generate the economic profile of a new therapy. Mohan Bala and Meghan Gallagher explain its use

Leadership Exchange: Thinking More Like a Patient

Leadership Exchange: Thinking More Like a Patient

A major information explosion is just the tip of the iceberg in the paradigm shift that is taking place between pharma, marketers and the patients that they serve. James Chase asks experts from across the patient-to-pharma spectrum how the industry can negotiate the new environment to successfully put patients first

Biotech Report: Ultra Man

Biotech Report: Ultra Man

Innovation is still valued in the orphan-drug space, but the reimbursement bar is rising. NPS Pharma's Eric Pauwels, who's launched five ultra-rare disease products, explains how these biotech brands can demonstrate their value. Marc Iskowitz reports

Top 100 Agencies 2014: Wunderman World Health

Top 100 Agencies 2014: Wunderman World Health

Employing the tools clients and audiences want yields success

Top 100 Agencies 2014: W2O Group

Top 100 Agencies 2014: W2O Group

A steady focus on data analytics brings a new level of relevance

Top 100 Agencies 2014: Vogel Farina

Top 100 Agencies 2014: Vogel Farina

Specialty, long VF's sweet spot, has them on a major growth spurt

Top 100 Agencies 2014: Triple Threat Communications

Top 100 Agencies 2014: Triple Threat Communications

Putting client success first reaps increasing rewards for this agency

Top 100 Agencies 2014: Topin & Associates

Top 100 Agencies 2014: Topin & Associates

At Chicago firm, new business and a new strategic partnership

Top 100 Agencies 2014: Sudler & Hennessey

Top 100 Agencies 2014: Sudler & Hennessey

Thinking globally leads this agency to continued solid performance

Top 100 Agencies 2014: STRIKEFORCE Communications

Top 100 Agencies 2014: STRIKEFORCE Communications

Bucking the "monolithic" model results in client, revenue growth

Top 100 Agencies 2014: StoneArch

Top 100 Agencies 2014: StoneArch

After 30 years in the business, still finding new avenues to explore

Top 100 Agencies 2014: Siren Interactive

Top 100 Agencies 2014: Siren Interactive

Chicago firm broadens its base beyond a rare-disease specialty

Top 100 Agencies 2014: Scout Marketing

Top 100 Agencies 2014: Scout Marketing

A focus on specialty pharma puts this agency in a solid position

Top 100 Agencies 2014: Saatchi & Saatchi Wellness

Top 100 Agencies 2014: Saatchi & Saatchi Wellness

Emerging from a consolidation with all of its strengths intact

Top 100 Agencies 2014: Rosetta

Top 100 Agencies 2014: Rosetta

Longtime "patient-centric" agency sets the engagement standard

Top 100 Agencies 2014: RevHealth

Top 100 Agencies 2014: RevHealth

Getting out of the "professional agency box" spurs major growth

Top 100 Agencies 2014: Renavatio Healthcare Communications

Top 100 Agencies 2014: Renavatio Healthcare Communications

Launch leaders: Agency excels at helping brands get to market

Top 100 Agencies 2014: Razorfish Healthware

Top 100 Agencies 2014: Razorfish Healthware

Changing technology opens a path to "business transformation"

Top 100 Agencies 2014: Purohit Navigation

Top 100 Agencies 2014: Purohit Navigation

Chicago firm leverages specialty expertise into growing revenues

Top 100 Agencies 2014: PulseCX

Top 100 Agencies 2014: PulseCX

A new name illustrates this agency's new strategy and focus

Top 100 Agencies 2014: Publicis Life Brands Medicus

Top 100 Agencies 2014: Publicis Life Brands Medicus

Getting out of its comfort zone lets agency pursue new opportunities

Top 100 Agencies 2014: Palio+Ignite

Top 100 Agencies 2014: Palio+Ignite

New collaboration at the top invigorates inVentiv Health shop

Top 100 Agencies 2014: Pacific Communications

Top 100 Agencies 2014: Pacific Communications

Keeping an eye on the media mix while never losing sight of digital

Top 100 Agencies 2014: Ogilvy CommonHealth Worldwide

Top 100 Agencies 2014: Ogilvy CommonHealth Worldwide

An agency with a big name and clients takes a personal approach

Top 100 Agencies 2014: Neon

Top 100 Agencies 2014: Neon

Agency comes out swinging after Pfizer hit, and scores a comeback

Top 100 Agencies 2014: The Navicor Group

Top 100 Agencies 2014: The Navicor Group

A broader scope opens the path to a new set of opportunities

Top 100 Agencies 2014: Natrel Communications

Top 100 Agencies 2014: Natrel Communications

Tempering a diversification drive with a focus on the fundamentals

Top 100 Agencies 2014: MicroMass Communications

Top 100 Agencies 2014: MicroMass Communications

Understanding patient behavior helps this agency bring in clients

Top 100 Agencies 2014: MedThink Communications

Top 100 Agencies 2014: MedThink Communications

A nimble, flexible approach attracts a diversified client base

Top 100 Agencies 2014: Mc|K Healthcare

Top 100 Agencies 2014: Mc|K Healthcare

Change is a constant across the board for this Boston-based firm

Top 100 Agencies 2014: McCann Torre Lazur

Top 100 Agencies 2014: McCann Torre Lazur

Launches and orphan brands lead agency to its "best year ever"

Top 100 Agencies 2014: McCann Regan Campbell Ward

Top 100 Agencies 2014: McCann Regan Campbell Ward

Even a year filled with changes "didn't change who we were"

Top 100 Agencies 2014: McCann Managed Markets

Top 100 Agencies 2014: McCann Managed Markets

"Great growth, new clients, new work" at this McCann shop

Top 100 Agencies 2014: McCann HumanCare

Top 100 Agencies 2014: McCann HumanCare

A new leader aims to transform both his agency—and healthcare

The 2015 healthcare agency questionnaire, for firms hoping to be featured in the Top 100 Agencies issue, is live. Click here to be considered.

Email Newsletters